ReShape Lifesciences Inc. (RSLS) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 0.36 High: 0.38

52 Week Range

Low: 0.30 High: 29.00

Liquidityliquidity Moderate

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $4 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    1.2

  • Industry P/EIndustry P/E information

    87.38

  • Debt to EquityDebt to Equity information

    0

  • ROEROE information

    -2.22 %

  • ROCEROCE information

    --

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    -0.35

  • EPSEPS information

    --

10 Years Aggregate

CFO

$-191.71 Mln

EBITDA

$-226.79 Mln

Net Profit

$-405.33 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
ReShape Lifesciences (RSLS)
-91.83 -43.67 -91.78 -96.26 -94.92 -86.49 -71.41
BSE Sensex*
2.52 3.37 6.44 8.80 12.18 20.37 11.43
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 25-Apr-2025  |  *As on 28-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
2021
2020
2019
2018
ReShape Lifesciences (RSLS)
-68.84 -96.30 -91.78 -53.80 -38.26 125.49 -82.60
S&P Small-Cap 600
7.01 13.89 -17.42 25.27 9.57 20.86 -9.70
BSE Sensex
8.10 18.74 4.44 21.99 15.75 14.38 5.87

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
24.96 1,186.57 -- 0.74
123.41 4,306.02 57.4 4.76
94.61 5,591.89 46.38 8.89
299.78 11,550.00 278.74 3.65

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally...  invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.  Read more

Edit peer-selector-edit
loading...
loading...

FAQs for ReShape Lifesciences Inc. (RSLS)

The total asset value of ReShape Lifesciences Inc (RSLS) stood at $ 9 Mln as on 31-Mar-25

The share price of ReShape Lifesciences Inc (RSLS) is $0.37 (NASDAQ) as of 25-Apr-2025 16:28 EDT. ReShape Lifesciences Inc (RSLS) has given a return of -94.92% in the last 3 years.

ReShape Lifesciences Inc (RSLS) has a market capitalisation of $ 4 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.

The P/B ratio of ReShape Lifesciences Inc (RSLS) is 1.20 times as on 25-Apr-2025, a 67% discount to its peers’ median range of 3.59 times.

Since, TTM earnings of ReShape Lifesciences Inc (RSLS) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ReShape Lifesciences Inc (RSLS) and enter the required number of quantities and click on buy to purchase the shares of ReShape Lifesciences Inc (RSLS).

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

The CEO & director of Mr. Dan W. Gladney. is ReShape Lifesciences Inc (RSLS), and CFO & Sr. VP is Mr. Dan W. Gladney.

There is no promoter pledging in ReShape Lifesciences Inc (RSLS).

ReShape Lifesciences Inc. (RSLS) Ratios
Return on equity(%)
--
Operating margin(%)
-56.65
Net Margin(%)
-85.14
Dividend yield(%)
0

No, TTM profit after tax of ReShape Lifesciences Inc (RSLS) was $0 Mln.